In Cash & Henderson Drugs, Inc v. Johnson & Johnson, Case No. 12-4689 (2nd Cir. Aug. 27, 2015), the Second Circuit upheld a summary judgment in favor of defendant pharmaceutical manufacturers accused of price discrimination.
Retail pharmacies alleged – and the defendant manufacturers conceded – that the drug companies had offered lower drug pricing to staff-model HMOs and pharmacy benefit managers. The retail pharmacies alleged that the price discounts amounted to unlawful price discrimination under the Robinson-Patman Act.
Through court-supervised discovery, the plaintiffs attempted to assemble “matching” evidence showing that customers they lost ended up purchasing from the favored purchasers. However, the evidence showed that only 1%-3% of potential lost customers in plaintiffs’ records could be identified as customers who later filled prescriptions with a favored purchaser.
The Second Circuit held that this de minimis loss of customers was insufficient to establish a competitive injury. The court held that although FTC v. Morton Salt Co., 334 U.S. 37, 50-51 (1948), also permits a discrimination claim to be predicated upon a substantial discount to a competitor over a significant period of time, after Volvo Trucks North America v. Reeder-Simco GMC, Inc., 546 U.S. 164, 180 (2006) (holding that price discrimination must affect “substantially” competition between the favored purchaser and the plaintiff), “if the loss attributable to impaired competition is de minimis, then the challenged practice cannot be said to have had a ‘substantial’ affect [sic] on competition.”
Cash & Henderson is yet further evidence of the courts’ repeated attempts to limit the reach of the Robinson-Patman Act and harmonize it with the intent to protect competition (not competitors) that animates the Sherman Act.